Business
Bionik Laboratories to Present at the 28th Annual ROTH Conference
Bionik Laboratories to Present at the 28th Annual ROTH Conference.
About this update from Bionik Laboratories Corp.
[{"type":"text","content":"\n\n\n\nBionik Laboratories to Present at the 28th Annual ROTH Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nBionik Laboratories to Present at the 28th Annual ROTH Conference\nPR Newswire\nTORONTO, March 10, 2016\n\n\n\n- Presentation with live webcast on Wednesday, March 16 at 7:00 a.m. PT - \n\n- Presentation to include Company's planned acquisition of Interactive Motion Technologies, Inc. - \n\n\n\nTORONTO, March 10, 2016 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQX: BNKL), a medical device and robotics company with a focus on developing technologies and solutions for individuals with neurological disorders (\"Bionik\" or the \"Company\"), announced today that Peter Bloch, Chief Executive Officer and Chairman of the Board, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016 at 7:00 a.m. PT in Dana Point, California. \n\n\nMr. Bloch will provide a corporate update and will discuss the progress of its primary product, ARKE™, a robotic lower-body exoskeleton device designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. Mr. Bloch will also discuss Bionik's recent news announcing that the Company entered into a definitive merger agreement with Interactive Motion Technologies, Inc. (\"IMT\"), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic tools for neurorehabilitation. The transaction is subject to customary closing conditions, including approval by IMT's shareholders. Bionik expects the transaction to close in April 2016. \n\nIMT's product line includes three upper extremity clinical rehabilitation products currently on the market for clinical use, a lower-body product available for research use being developed for clinical release, and an exciting new product candidate for gait in development at MIT. IMT has established a growing body of clinical data for these products. The clinical products have U.S. Food and Drug Administration (FDA) approval and are currently sold in over 20 countries, including the United ...